Last reviewed · How we verify
Formosa Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| APP13007, 0.05% | APP13007, 0.05% | phase 3 | Prostaglandin F receptor agonist | FP receptor (prostaglandin F receptor) | Ophthalmology |
Therapeutic area mix
- Diabetes · 1
- Ophthalmology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Allergan · 2 shared drug classes
- Pfizer · 2 shared drug classes
- Medical University of Vienna · 2 shared drug classes
- AJU Pharm Co., Ltd. · 1 shared drug class
- AceLink Therapeutics, Inc. · 1 shared drug class
- Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
- Abbott · 1 shared drug class
- Aciex Therapeutics, Inc. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Formosa Pharmaceuticals, Inc.:
- Formosa Pharmaceuticals, Inc. pipeline updates — RSS
- Formosa Pharmaceuticals, Inc. pipeline updates — Atom
- Formosa Pharmaceuticals, Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Formosa Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/formosa-pharmaceuticals-inc. Accessed 2026-05-17.